Sotera Health Co key statistics and ratios
In fiscal 2025, Sotera Health Co had return on equity of 15.4%, a net margin of 6.7%, debt equal to 358.0% of equity and a current ratio of 2.46. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 50.8% | 54.2% | 55.7% | 55.5% | 55.0% | 54.7% | 55.5% | 55.0% |
| Operating margin | 23.6% | 25.2% | 27.6% | 24.7% | 26.4% | 27.0% | — | — |
| Net margin | −2.7% | −4.7% | 12.5% | −23.3% | 4.9% | 4.0% | 6.7% | 13.4% |
| Free-cash-flow margin | 11.8% | 8.2% | 19.3% | 9.5% | −34.6% | 4.1% | 12.8% | 9.3% |
| Return on equity | — | — | 22.5% | −49.9% | 12.9% | 10.5% | 15.4% | 25.7% |
| Return on assets | — | −1.4% | 4.2% | −7.9% | 1.6% | 1.4% | 2.5% | 5.0% |
| Asset turnover | — | 0.30 | 0.34 | 0.34 | 0.34 | 0.35 | 0.37 | 0.37 |
| Current ratio | — | 2.24 | 2.15 | 0.81 | 2.42 | 2.75 | 2.46 | 2.80 |
| Debt to equity | — | 412.0% | 300.9% | 560.6% | 509.4% | 557.1% | 358.0% | 325.4% |
| Effective tax rate | — | — | 33.3% | — | 51.5% | 61.0% | 47.2% | 38.1% |
| SG&A as % of revenue | 18.9% | 21.8% | 21.3% | 24.5% | 22.6% | 22.0% | 21.7% | 21.1% |
| Capital spending as % of revenue | 7.4% | 6.5% | 11.0% | 18.2% | 20.5% | 16.3% | 11.9% | 14.8% |
| Free cash flow ÷ net income | — | — | 153.5% | — | −706.0% | 101.6% | 191.4% | 68.9% |
| Dividends ÷ net income | — | — | 0.0% | — | — | — | — | — |
| Dividends and buybacks ÷ free cash flow | 753.0% | 50.7% | 0.0% | 0.0% | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 55.4% | 56.6% | 53.2% | 56.6% | 57.0% | 54.7% | 52.5% | 55.4% |
| Operating margin | 28.2% | 30.0% | — | — | — | — | — | — |
| Net margin | 6.0% | 4.2% | −5.2% | 2.7% | 15.5% | 11.5% | 9.5% | 16.7% |
| Free-cash-flow margin | 21.4% | −3.5% | 14.0% | 8.9% | 11.2% | 17.3% | −6.0% | 13.1% |
| Current ratio | 2.88 | 2.75 | 2.46 | 2.47 | 2.38 | 2.46 | 2.82 | 2.80 |
| Debt to equity | 473.4% | 549.0% | 536.2% | 433.7% | 389.3% | 353.2% | 343.5% | 321.4% |
| SG&A as % of revenue | 21.7% | 21.3% | 24.8% | 23.4% | 20.3% | 19.0% | 24.4% | 21.2% |
Financial health
- Short-term assets cover short-term liabilities $646m of assets due within a year against $231m of liabilities due within a year.
- Short-term assets cover long-term liabilities $646m short-term assets against $2.4bn of longer-dated liabilities.
- More cash than debt $357m of cash against $2.1bn of debt.
- Debt below 40% of shareholders' equity Debt is 321% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 297% to 321% over five years.
- A year's operating cash flow covers at least 20% of debt $292m of operating cash flow against $2.1bn of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Strong moat
How hard Sotera Health's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 14 / 20
Cash operating profit has been a median 11.3% of total assets over 5 years.
- Pricing power 19 / 20
Gross margin has been a median 55.2%, moving by 0.5 percentage points (standard deviation) across 6 years.
- Durability 19 / 20
Operating margin has been a median 26.4%; its worst year was 24.7%.
- Cash conversion 13 / 20
Free cash flow was positive in 5 of 6 years, at a median 9.6% of revenue.
- Discipline 12 / 20
The diluted share count rose 10.3% over five years; stock-based pay has been a median 2.8% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (77 before it).
Compare with peers
- Bio-Techne statistics
- Repligen Corp statistics
- Neogenomics Inc statistics
- Qiagen N.V. statistics
- 10x Genomics, Inc. statistics
Head to head: SHC vs TECHRGEN vs SHCNEO vs SHC
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies